AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

Background Accumulating data implicate interleukin (IL)-33, a proinflammatory cytokine released locally upon epithelial cell damage, in the pathogenesis of COPD. In a phase 2 study, itepekimab, a human monoclonal antibody against IL-33, reduced exacerbations and improved lung function in a subgroup...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaus F. Rabe, Fernando J. Martinez, Surya P. Bhatt, Tomotaka Kawayama, Borja G. Cosio, Robert M. Mroz, Maarten M. Boomsma, Helene Goulaouic, Michael C. Nivens, Michel Djandji, Xavier Soler, Ying Liu, Matthew P. Kosloski, Christine R. Xu, Nikhil Amin, Heribert Staudinger, David J. Lederer, Raolat M. Abdulai
Format: Article
Language:English
Published: European Respiratory Society 2024-09-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/10/5/00718-2023.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://openres.ersjournals.com/content/10/5/00718-2023.full

Similar Items